Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 10/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.68 |
| ▸ | MAPT | P10636 | 10/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.68 |
| ▸ | NPC1 | O15118 | 9/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.68 |
| ▸ | GAA | P10253 | 8/20 | 0.68 |
| ▸ | RAB9A | P51151 | 8/20 | 0.68 |
| ▸ | GFER | P55789 | 4/20 | 0.68 |
| ▸ | GLA | P06280 | 4/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 9/20 | 0.65 |
| ▸ | TP53 | P04637 | 6/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.65 |
| ▸ | RELA | Q04206 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11443268 | 0.90 | MEN1 (0.65) | RHEBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL11440973 | 0.90 | MEN1 (0.65) | RHEBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15443951 | 0.88 | MEN1 (0.79) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15443910 | 0.86 | MEN1 (0.77) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL25206796 | 0.83 | RHEB (0.69) | RHEBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL10736415 | 0.83 | RHEB (0.69) | RHEBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL30943399 | 0.83 | RHEB (0.69) | RHEBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL30615082 | 0.83 | RHEB (0.73) | RHEBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9000174 | 0.83 | RHEB (0.73) | RHEBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL30726452 | 0.83 | PRMT1 (0.73) | RHEBMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20050277686-A1 | Benzimidazole compounds for regulating IgE | SIRCAR JAGADISH C | 2005-12-15 | — | — | US | disclosed |
| EP-1555020-A2 | Benzimidazole derivatives as modulators IgE | Avanir Pharmaceuticals (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6919366-B2 | Benzimidazole derivatives as modulators of IgE | AVANIR PHARMACEUTICALS (US) | 2005-07-19 | — | — | US | disclosed |
| US-6911462-B2 | Benzimidazole compounds for regulating IgE | AVANIR PHARMACEUTICALS (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050075343-A1 | Benzimidazole derivatives as modulators of IgE | SIRCAR JAGADISH C (US) | 2005-04-07 | — | — | US | disclosed |
| EP-1077700-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE | AVANIR PHARMACEUTICALS (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20030100582-A1 | Benzimidazole compounds for regulating IgE | AVANIR PHARMACEUTICALS | 2003-05-29 | — | — | US | disclosed |
| US-20030004203-A1 | Benzimidazole derivatives as modulators of IgE | AVANIR PHARMACEUTICALS | 2003-01-02 | — | — | US | disclosed |
| US-6369091-B1 | ANTIALLERGENS | AVANIR PHARMACEUTICALS | 2002-04-09 | — | — | US | disclosed |
| US-6303645-B1 | USEFUL IN THERAPY OF ALLERGY AND/OR ASTHMA OR ANY DISEASES WHERE IMMUNOGLOBULIN E (IGE) IS PATHOGENIC | AVANIR PHARMACEUTICALS | 2001-10-16 | — | — | US | disclosed |
| EP-1079830-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | Avanir Pharmaceuticals (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-1077700-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE | Avanir Pharmaceuticals (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999061019-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE | AVANIR PHARMACEUTICALS (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999061020-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | AVANIR PHARMACEUTICALS (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100582-A1 | Benzimidazole compounds for regulating IgE | FCER2, SERPINB1, BRPF3 | RHEB 2827/4885MEN1 4827/4885KMT2A 660/4885 |
| US-20050277686-A1 | Benzimidazole compounds for regulating IgE | FCER2, SERPINB1, BRPF3 | RHEB 2827/4885MEN1 4827/4885KMT2A 660/4885 |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | RHEB 1/4885MEN1 254/4885KMT2A 2481/4885 |
| US-20030004203-A1 | Benzimidazole derivatives as modulators of IgE | IGF1R, IGFBP1, IGFBP4 | RHEB 2608/4885MEN1 3457/4885KMT2A 2109/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | RHEB 1/4885MEN1 169/4885KMT2A 3149/4885 |
| US-20050075343-A1 | Benzimidazole derivatives as modulators of IgE | FCER2, HRH4, DBI | RHEB 4042/4885MEN1 4852/4885KMT2A 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.